Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Sees Significant Decrease in Short Interest

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw a large decline in short interest in July. As of July 31st, there was short interest totaling 28,818 shares, a decline of 54.9% from the July 15th total of 63,921 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 465,929 shares, the days-to-cover ratio is presently 0.1 days.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on CHGCY. The Goldman Sachs Group raised shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. UBS Group cut shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Finally, Zacks Research raised shares of Chugai Pharmaceutical to a “hold” rating in a research note on Friday, May 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Performance

CHGCY stock opened at $21.55 on Monday. The company’s 50 day moving average price is $22.57 and its 200 day moving average price is $25.85. Chugai Pharmaceutical has a fifty-two week low of $20.27 and a fifty-two week high of $34.84. The firm has a market capitalization of $70.93 billion, a price-to-earnings ratio of 23.42 and a beta of 0.60.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.71%. The company had revenue of $2.14 billion during the quarter, compared to the consensus estimate of $2.38 billion. Equities analysts forecast that Chugai Pharmaceutical will post 0.96 EPS for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.